Page last updated: 2024-08-21

quinazolines and entinostat

quinazolines has been researched along with entinostat in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bunn, PA; Hirsch, FR; Jotte, RM; Konduri, K; Neubauer, MA; Ruxer, RL; Spira, AI; Varella-Garcia, M; Witta, SE1
Chen, M; Hu, L; Yang, X; Zhang, Q1
Bartholomeusz, C; Hortobagyi, GN; Humphries, J; Lee, J; Mansour, O; Ordentlich, P; Ueno, NT1

Trials

1 trial(s) available for quinazolines and entinostat

ArticleYear
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-20, Volume: 30, Issue:18

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Middle Aged; Pyridines; Quinazolines

2012

Other Studies

2 other study(ies) available for quinazolines and entinostat

ArticleYear
Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats.
    Xenobiotica; the fate of foreign compounds in biological systems, 2014, Volume: 44, Issue:11

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Chromatography, Liquid; Drug Interactions; Lapatinib; Male; Mass Spectrometry; Pyridines; Quinazolines; Rats; Rats, Sprague-Dawley

2014
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
    Breast cancer research and treatment, 2014, Volume: 146, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Lapatinib; Mice; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays

2014